Protein phosphatase 3 (formerly 2B), catalytic subunit, alpha isoform, also known as PPP3CA, is a human gene.[1] Calcineurin (CN) is a protein phosphatase also known as protein phosphatase 2B (PP2B). Calcineurin is responsible for activating the transcription of interleukin 2 (IL-2), that stimulates the growth and differentiation of T cell response. In immunosuppressive therapy it is inhibited by cyclosporin, pimecrolimus (Elidel) and tacrolimus (FK506) - these drugs are known as calcineurin inhibitors. Calcineurin dephosphorylates Nuclear factor of activated T cell, cytoplasmic component (NFATc), a transcription factor that can then go into the nucleus and turn on genes involved in IL-2 synthesis.
Calcineurin is linked to receptors for two brain chemicals, NMDA and dopamine. An experiment with genetically-altered mice that could not produce calcineurin showed similar symptoms as in humans with schizophrenia: impairment in working memory, attention deficits, aberrant social behavior and several other abnormalities characteristic of schizophrenia.[3]
increase in the cytoplasmic level of calcium, which [2] activates calcineurin, by binding a regulatory subunit and activating calmodulin binding. Calcineurin induces different transcription factors (NF-ATs) that are important in the transcription of IL-2 genes. IL-2 activates T-helper lymphocytes and induces the production of other cytokines. In this way, it governs the action of cytotoxic lymphocytes and NK cells. The amount of IL-2 being produced by the T-helper cells is believed to influence the extent of the immune response significantly.
Heart disease hits people with diabetes twice as often as people without diabetes. In those with diabetes, cardiovascular complications occur at an earlier age and often result in premature death, making heart disease the major killer of diabetic people. Cardiolipin has recently been found to be deficient in the heart at the earliest stages of diabetes, possibly due to a lipid-digesting enzyme that becomes more active in diabetic heart muscle.[1]
Recent research on luohan guo suggests that the mogroside works as an antioxidant[12] and that it helps to prevent cancer.[13][14] The use of luohan guo as a remedy for diabetes and overweight has been mentioned, as it can be used as a substitute for sugar.[15] Luohan guo has been shown to be useful against the Epstein-Barr virus. [16] The plant also contains a glycoprotein called momorgrosvin, which has been shown to inhibit ribosomal protein synthesis[17]
A well-controlled study showed that selenium intake is positively correlated with the risk of developing type II diabetes. Because high serum selenium levels are positively associated with the prevalence of diabetes, and because selenium deficiency is rare, supplementation is not recommended in well-nourished populations such as the U.S.[45]
Adiponectin was first characterised in mice as a transcript overexpressed in preadipocytes (precursors of fat cells) differentiating into adipocytes. The human homologue was identified as the most abundant transcript in adipose tissue. Contrary to expectations, despite being produced in adipose tissue, adiponectin was found to be decreased in obesity. This downregulation has not been fully explained. The gene was localised to chromosome 3p27, a region highlighted as affecting genetic susceptibility to type 2 diabetes and obesity. Supplementation by differing forms of adiponectin were able to improve insulin control, blood glucose and triglyceride levels in mouse models. The gene was investigated for
Similar to what has been discovered with the drug metformin, pterostilbene has been shown to lower blood glucose levels in rats by as much as 42 percent, although at this point very little research has been conducted to conclusively follow this out.
Linagliptin (BI-1356, expected trade name Ondero) is a DPP-4 inhibitor developed by Boehringer Ingelheim undergoing research for type II diabetes. It is currently in a Phase III clinical trial.
Poor management of type 1 diabetes mellitus, also known as insulin-dependent diabetes mellitus (IDDM), leads to an excessive amount of glucose and an insufficient amount of insulin in the bloodstream. This triggers the release of triglycerides from adipose (fat) tissue and catabolism (breakdown) of amino acids in muscle tissue. This results in a loss of both fat and lean mass, leading to a significant reduction in total body weight. Note that untreated type 1 diabetes mellitus will usually not produce weight loss, as these patients get acutely ill before they would have had time to lose weight. Myriad additional scientific considerations
Several alleles of HLA-DQB1 are associated with an increased risk of developing type 1 diabetes.[3][4][5] The locus also has the genetic name IDDM1 as it is the highest genetic risk for type 1 diabetes. Again the DQB1*0201 and DQB1*0302 alleles, particularly the phenotype DQB1*0201/*0302 has a high risk of late onset type 1 diabetes. The risk is partially shared with the HLA-DR locus (DR3 and DR4 serotypes).
Research dietitians are mostly involved with dietary related research in the clinical aspect of nutrition in disease states, public aspect on primary, secondary and sometimes tertiary health prevention and foodservice aspect in issues involving the food prepared for patients. Many registered dietitians also work with the biochemical aspects of nutrient interaction within the body. Research Dietitians normally work in a hospital or university research facilities. It should be noted that some Clinical dietitian's roles also involve research other than the normal clinical workload. Quality improvement in dietetics services is also one area of research.
National Diabetes Information Clearinghouse. National diabetes statistics. NIH publication 02–3892. 2002. Fact sheet. Available at: www.niddk.nih.gov/health/diabetes/pubs/dmstats/dmstats.htm. Accessed April 4, 2002. Harvard School of Public Health Baylor College of Medicine Latino Nutrition Coalition Latin American Diet Summit Consensus Statement
Glucomannan may be useful as a therapeutic adjunct for type 2 diabetes. It has been shown to improve the lipid profile and alleviate the fasting blood glucose levels of type 2 diabetics.[9]
Patrick Vallance and his London co-workers first noted the interference role for asymmetric dimethylarginine.[1] Today biochemical and clinical research continues into the role of ADMA in cardiovascular disease, diabetes mellitus, erectile dysfunction and certain forms of kidney disease.